Show simple item record

dc.contributor.authorAssi, Sulaf
dc.contributor.authorFergus, Suzanne
dc.contributor.authorStair, Jacqueline
dc.contributor.authorCorazza, Ornella
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2013-01-14T08:58:58Z
dc.date.available2013-01-14T08:58:58Z
dc.date.issued2011
dc.identifier.citationAssi , S , Fergus , S , Stair , J , Corazza , O & Schifano , F 2011 , ' Emergence and identification of new products of designer drug products from the internet ' , European Pharmaceutical Review , vol. 16 , no. 4 , pp. 68-72 . < http://www.europeanpharmaceuticalreview.com/ >
dc.identifier.issn1360-8606
dc.identifier.otherORCID: /0000-0002-7134-0665/work/70189306
dc.identifier.otherORCID: /0000-0001-7371-319X/work/98163892
dc.identifier.urihttp://hdl.handle.net/2299/9600
dc.descriptionOriginal article can be found at : http://www.europeanpharmaceuticalreview.com/ Copyright Russell Publishing Ltd. [Due to publisher restrictions full text of this article is not available in the UHRA]
dc.description.abstractDesigner drugs represent a rapidly expanding phenomenon particularly facilitated by their Internet availability. These drugs are continuously emerging as analogues of controlled substances (amfetamine, aminoindane, cathinone, phencyclidine, etc...) and once an analogue has been banned; another replacement analogue appears on the market. They are often made in unlicensed laboratories which can result in their poor quality. This highlights the importance of analysing these products through detecting both their identity and purity. However, most of the analysis methods focused on emerging analogues of cathinone and very few studied other newer analogues such as phencyclidine derivatives. This is due partly to the regulations surrounding the analysis, the time consuming analytical procedures and the technical skills involved. Analysis of these designer drugs in the literature included both the identification of drug products and monitoring of products consistency over a period of time. In all cases, the results showed that these products may contain a range of a single or mixture of components including: a designer drug, a pharmaceutical active agent, an excipient or inorganic material.en
dc.format.extent655166
dc.language.isoeng
dc.relation.ispartofEuropean Pharmaceutical Review
dc.titleEmergence and identification of new products of designer drug products from the interneten
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionMedicinal and Analytical Chemistry
dc.contributor.institutionNatural Product Chemistry and Drug Design
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Hazard Detection and Protection Research
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.contributor.institutionCentre for Future Societies Research
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.europeanpharmaceuticalreview.com/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record